The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Open accessAbstract
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using next-generation RNA sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN) samples and validated findings in tumors from a large cohort of patients (37 with NEPC, 169 with PCA, and 22 with BEN) using immunohistochemistry and FISH. We discovered significant overexpression and gene amplification of AURKA and MYCN in 40% of NEPC and 5% of PCA tumors, respectively, and evidence that they cooperate to induce a neuroendocrine phenotype in prostate cells. There was dramatic and enhanced sensitivity of NEPC (and MYCN overexpressing PCA) to Aurora kinase inhibitor therapy both in vitro and in vivo, with complete suppression of neuroendocrine marker expression following treatment. We propose that alterations in Aurora kinase A and N-myc are involved in the development of NEPC and that future clinical trials will help determine the efficacy of Aurora kinase inhibitor therapy. Significance: We report on the largest in-depth molecular analysis of NEPC and provide new insight into molecular events involved in the progression of prostate cancer. Cancer Discovery; 1(6); 487–95. ©2011 AACR. Read the Commentary on this article by Aparicio et al., p. 466 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citationThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citationTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
(1986) · Lung Cancer · doi:10.1016/s0169-5002(86)80023-x · Cited by 900
Hsu, J.-Y., Sun, Z.-W., Li, X., Reuben, M., Tatchell, K., Bishop, D. K., Grushcow, J. M., Brame, C. J., Caldwell, J. A., Hunt, D. F., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00034-9 · Cited by 858
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Molecular characterization of human prostate carcinoma cell lines
van Bokhoven, A., Varella‐Garcia, M., Korch, C., Johannes, W. U., Smith, E. E., Miller, H. L., Nordeen, S. K., Miller, G. J., & Lucia, M. S. (2003) · The Prostate · doi:10.1002/pros.10290 · Cited by 633
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schüttrumpf, L., Popov, N., Kenney, A. M., Schulte, J. H., Beijersbergen, R., Christiansen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.005 · Cited by 573
Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases
Wang, W., & Epstein, J. I. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318058a96b · Cited by 375
Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer
Setlur, S. R., Mertz, K. D., Hoshida, Y., Demichelis, F., Lupien, M., Perner, S., Sboner, A., Pawitan, Y., Andrén, O., Johnson, L. A., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn150 · Cited by 328
Self-citationHirano, D., Okada, Y., Minei, S., Takimoto, Y., & Nemoto, N. (2004) · European Urology · doi:10.1016/j.eururo.2003.11.032 · Cited by 303
Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
Vashchenko, N., & Abrahamsson, P.-A. (2005) · European Urology · doi:10.1016/j.eururo.2004.09.007 · Cited by 260
Mosquera, J.-M., Mehra, R., Regan, M. M., Perner, S., Genega, E. M., Bueti, G., Shah, R. B., Gaston, S., Tomlins, S. A., Wei, J. T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2927 · Cited by 234
Self-citationThe p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
Slack, A., Chen, Z., Tonelli, R., Pule, M., Hunt, L., Pession, A., & Shohet, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405495102 · Cited by 233
Yuan, T.-C., Veeramani, S., & Lin, M.-F. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0061 · Cited by 231
ERG gene rearrangements are common in prostatic small cell carcinomas
Lotan, T. L., Gupta, N. S., Wang, W., Toubaji, A., Haffner, M. C., Chaux, A., Hicks, J. L., Meeker, A. K., Bieberich, C. J., De Marzo, A. M., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.7 · Cited by 218
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing
Pflueger, D., Terry, S., Sboner, A., Habegger, L., Esgueva, R., Lin, P.-C., Svensson, M. A., Kitabayashi, N., Moss, B. J., MacDonald, T. Y., et al. (2011) · Genome Research · doi:10.1101/gr.110684.110 · Cited by 201
Self-citationUnusual and Underappreciated: Small Cell Carcinoma of the Prostate
Palmgren, J. S., Karavadia, S. S., & Wakefield, M. R. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.10.026 · Cited by 162
Williamson, S. R., Zhang, S., Yao, J. L., Huang, J., Antonio Lopez-beltran, B., Shen, S. S., Osunkoya, A. O., MacLennan, G. T., Montironi, R., & Liang Cheng, C. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.56 · Cited by 140
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor
Scheble, V. J., Braun, M., Beroukhim, R., Mermel, C. H., Ruiz, C. F., Wilbertz, T., Stiedl, A., Petersen, K., Reischl, M., Kuefer, R., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.87 · Cited by 129
Self-citationRSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries
Habegger, L., Sboner, A., Gianoulis, T. A., Rozowsky, J. S., Agarwal, A., Snyder, M. P., & Gerstein, M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq643 · Cited by 114
Self-citationBerruti, A., Mosca, A., Porpiglia, F., Bollito, E., Tucci, M., Vana, F., Cracco, C. M., TORTA, M., Russo, L. M., Cappia, S., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.018 · Cited by 101
Hansel, D. E., Nakayama, M., Luo, J., Abukhdeir, A. M., Park, B. H., Bieberich, C. J., Hicks, J. L., Eisenberger, M. A., Nelson, W. G., Mostwin, J. L., et al. (2009) · The Prostate · doi:10.1002/pros.20910 · Cited by 78
Meulenbeld, H. J., Bleuse, J. P., Vinci, E. M., Raymond, É., Vitali, G., Santoro, A., Dogliotti, L., Berardi, R., Cappuzzo, F., Tagawa, S. T., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11404.x · Cited by 77
Self-citationRegulation of N-myc expression in development and disease
Strieder, V., & Lutz, W. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00020-4 · Cited by 60
Use of irinotecan for treatment of small cell carcinoma of the prostate
Tung, W., Wang, Y., Gout, P. W., Liu, D., Gleave, M., & Wang, Y. (2010) · The Prostate · doi:10.1002/pros.21283 · Cited by 27
Self-citation
Cited by
The Landscape of Circular RNA in Cancer
Vo, J. N., Cieslik, M., Zhang, Y., Shukla, S., Xiao, L., Zhang, Y., Wu, Y.-M., Dhanasekaran, S. M., Engelke, C. G., Cao, X., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.021 · Cited by 1,738
Self-citationDivergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citation
Metadata
- Authors
- Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., Dhir, R., Nelson, J. B., de la Taille, A., Allory, Y., Gerstein, M. B., Perner, S., Pienta, K. J., Chinnaiyan, A. M., Wang, Y., Collins, C. C., Gleave, M. E., Demichelis, F., Nanus, D. M., & Rubin, M. A.
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 487-495
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2130955565
- Cited by
- 999
- References
- 27
- FWCI
- 28.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.